The newly granted patent, EP3927337, which will have an effective date of February 14, 2024, and an expiry date of no earlier than 2040, is expected to cov...
Under the partnership with Pfizer, Ultromics will research and pursue FDA clearance for its EchoGo® Amyloidosis algorithm that already has Breakthrough...
Illumina Ventures Labs is part of Illumina Ventures, the premier genomics and precision health venture firm supporting early-stage companies transforming h...
Approval by the Medicines and Healthcare products Regulatory Agency (MHRA) of AGAMREE® in the United Kingdom follows marketing authorization for this...
Fortrea , a leading global contract research organization (CRO), today announced an industry partnership with founding members Veeva Systems Inc., a l...
Ribbon cutting and commissioning of a multipurpose state-of-the-art Antibody-Drug Conjugate (ADC) manufacturing facility that expands capacity by approxi...
Roivant (Nasdaq: ROIV) announced the completion of the previously announced acquisition by Roche (SIX: RO, ROG; OTCQX: RHHBY) of Telavant, for an upf...
RoslinCT, a cell and gene therapy Contract Development and Manufacturing Organisation (‘CDMO’) dedicated to developing therapies for patients w...
Freeline shareholders to receive $6.50 per American Depositary Share, a 51% premium over closing price prior to announcement of Syncona’s initial pro...
Major Milestone Met in AI-Powered Fight Against Lung Cancer Global initiative gains significant ground in digitally identifying cancer risk before s...
Approval is the culmination of ten years of clinical research and development of the Medtronic renal denervation technology Medtronic plc (NYSE: MDT), a ...
- First regulatory authorization of a CRISPR-based gene-editing therapy in the world – - CASGEVY is indicated for the treatment of sickle cell...
T-Therapeutics raises £48 million Series A for development of next generation TCR therapeutics to transform cancer treatment Fundraise led by Sofin...
Seven major research projects to receive more than £14 million to develop new tests, treatments and devices for neurodegenerative diseases includin...
© 2024 Biopharma Boardroom. All Rights Reserved.
